MEK drives cyclin D1 hyperelevation during geroconversion

Cell Death and Differentiation

Volumn 20, Issue 9, 2013, Pages 1241-1249

  Leontieva, O V ^a   Demidenko, Z N ^a   Blagosklonny, M V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

aging; cancer; cell cycle; MEK; rapamycin; senescence

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BETA GALACTOSIDASE; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NUTLIN 3; P21 ACTIVATED KINASE; PALBOCICLIB; PROTEIN P16; RAPAMYCIN; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL AGING; CELL CYCLE; CELL LINE; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION;

ANTIBIOTICS, ANTINEOPLASTIC; BENZAMIDES; BUTADIENES; CELL AGING; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE 1; NEOPLASM PROTEINS; NITRILES; PIPERAZINES; PYRIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84882285836     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.86     Document Type: Article

References (72)

1. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
2. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle 2002; 1: 103-110.
3. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008; 121: 3853-3857.
4. Bartek J, Lukas J. DNA repair: Cyclin D1 multitasks. Nature 2012; 474: 171-172.
5. Blagosklonny MV. Cell senescence and hypermitogenic arrest. EMBO Rep 2003; 4: 358-362.
6. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7: 3355-3361.
7. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging 2012; 4: 159-165.
8. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12: 3008-3019.
9. Campisi J, D'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729-740.
10. Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci 2011; 124: 68-81.
11. Faraonio R, Salerno P, Passaro F, Sedia C, Iaccio A, Bellelli R et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ 2012; 19: 713-721.
12. Cahu J, Bustany S, Sola B. Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells. Cell Death Dis 2012; 3: e446.
13. Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC et al. p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene 2000; 19: 2165-2170.
14. Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012; 11: 4642-4649.
15. Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Aging 2009; 1: 1008-1016.
16. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8: 1896-1900.
17. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107: 9660-9664.
18. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 2012; 109: 13314-13318.
19. Serrano M, Lim AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK1A. Cell 1997; 88: 593-602.
20. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002; 22: 3497-3508.
21. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol 2001; 13: 748-753.
22. Itahana K, Dimri G, Campisi J. Regulation of cellular senescence by p53. Eur J Biochem 2001; 268: 2784-2791.
23. Ben-Porath I, Weinberg RA. When cells get stressed: an integrative view of cellular senescence. J Clin Invest 2004; 113: 8-13.
24. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130: 223-233.
25. Serrano M. Dissecting the role of mTOR complexes in cellular senescence. Cell Cycle 2012; 11: 2231-2232.
26. Malumbres M, De Castro IP, Hernandez MI, Jimenez M, Corral T, Pellicer A. Cellular response to oncogenic Ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol 2000; 20: 2915-2925.
27. Blagosklonny MV. The mitogen-activated protein kinase pathway mediates growth arrest or E1A-dependent apoptosis in SKBr3 human breast cancer cells. Int J Cancer 1998; 78: 511-517.
28. Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, Lessard F, Moiseeva O, Forest V et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev 2013; 27: 900-915.
29. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013; 493: 338-345.
30. Gems DH, de la Guardia YI. Alternative perspectives on aging in C. Elegans: reactive oxygen species or hyperfunction? Antioxid Redox Signal 2012; 19: 321-329.
31. Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 2012; 11: 2391-2401.
32. Lucibello FC, Sewing A, Brusselbach S, Burger C, Muller R. Deregulation of cyclins D1 and E and suppression of cdk2 and cdk4 in senescent human fibroblasts. J Cell Sci 1993; 105(Pt 1): 123-133.
33. Dulic V, Drullinger LF, Lees E, Reed SI, Stein GH. Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci USA 1993; 90: 11034-11038.
34. Wong H, Riabowol K. Differential CDK-inhibitor gene expression in aging human diploid fibroblasts. Exp Gerontol 1996; 31: 311-325.
35. Atadja P, Wong H, Veillete C, Riabowol K. Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res 1995; 217: 205-216.
36. Fukami-Kobayashi J, Mitsui Y. The regulation of cyclin D1 expression in senescent human fibroblasts. Exp Cell Res 1998; 241: 435-444.
37. Fukami-Kobayashi J, Mitsui Y. Cyclin D1 inhibits cell proliferation through binding to PCNA and cdk2. Exp Cell Res 1999; 246: 338-347.
38. Morisaki H, Ando A, Nagata Y, Pereira-Smith O, Smith JR, Ikeda K et al. Complex mechanisms underlying impaired activation of Cdk4 and Cdk2 in replicative senescence: roles of p16, p21, and cyclin D1. Exp Cell Res 1999; 253: 503-510.
39. Moon SK, Cha BY, Kim CH. In vitro cellular aging is associated with enhanced proliferative capacity, G1 cell cycle modulation, and matrix metalloproteinase-9 regulation in mouse aortic smooth muscle cells. Arch Biochem Biophys 2003; 418: 39-48.
40. Burton DG, Sheerin AN, Ostler EL, Smith K, Giles PJ, Lowe J et al. Cyclin D1 overexpression permits the reproducible detection of senescent human vascular smooth muscle cells. Ann N Y Acad Sci 2007; 1119: 20-31.
41. Darzynkiewicz Z. Running m(o)TOR with the brakes on leads to catastrophe at mitosis. Cell Cycle 2012; 11: 4494.
42. Fu M, Wang C, Rao M, Wu X, Bouras T, Zhang X et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem 2005; 280: 29728-29742.
43. Casimiro MC, Pestell RG. Cyclin d1 induces chromosomal instability. Oncotarget 2012; 3: 224-225.
44. Knudsen KE. Cyclin D1 goes metabolic: dual functions of cyclin D1 in regulating lipogenesis. Cell Cycle 2012; 11: 3533-3534.
45. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 1999; 19: 1346-1358.
46. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009; 8: 1888-1895.
47. Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 2008; 18: 1269-1277.
48. Salmond RJ, Emery J, Okkenhaug K, MAPK Zamoyska R. phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J Immunol 2009; 183: 7388-7397.
49. Bessard A, Fremin C, Ezan F, Coutant A, Baffet G. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 2007; 212: 526-536.
50. Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, Kalurupalle S et al. p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. Oncogene 2007; 26: 6954-6958.
51. Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L et al. c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 2002; 277: 23065-23075.
52. Lehman JA, Calvo V, Gomez-Cambronero J. Mechanism of ribosomal p70S6 kinase activation by granulocyte macrophage colony-stimulating factor in neutrophils: cooperation of a MEK-related, THR421/SER424 kinase and a rapamycin-sensitive, m-TOR-related THR389 kinase. J Biol Chem 2003; 278: 28130-28138.
53. Pospelova TV, Leontieva OV, Bykova TV, Zubova SG, Pospelov VA, Blagosklonny MV. Suppression of replicative senescence by rapamycin in rodent embryonic cells. Cell Cycle 2012; 11: 2402-2407.
54. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996; 227: 564-569.
55. Ye C, Zhang X, Wan J, Chang L, Hu W, Bing Z et al. Radiation-induced cellular senescence results from a slippage of long-term G 2 arrested cells into G 1 phase. Cell Cycle 2013; 12: 1424-1432.
56. Coleman ML, Marshall CJ, Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. Embo J 2003; 22: 2036-2046.
57. Santra MK, Wajapeyee N, Green MR. F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 2009; 459: 722-725.
58. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML et al. Regulation of cyclin D1 by calpain protease. J Biol Chem 1997; 272: 28479-28484.
59. Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 2006; 26: 4612-4627.
60. Averous J, Fonseca BD, Proud CG. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 2008; 27: 1106-1113.
61. Cohen JD, Gard JM, Nagle RB, Dietrich JD, Monks TJ, Lau SS. ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. Toxicol Sci 2011; 124: 75-87.
62. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle 2011; 10: 57-67.
63. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging 2010; 2: 344-352.
64. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48: 2388-2406.
65. Leontieva OV, Demidenko ZN, Gudkov AV, Blagosklonny MV. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One 2011; 6: e26126.
66. Blagosklonny M. Answering the ultimate question 'What is the Proximal Cause of Aging?'. Aging 2012; 4: 861-877.
67. Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, Albrecht JH. Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem 2003; 278: 3656-3663.
68. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6686.
69. Zacharek SJ, Xiong Y, Shumway SD. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res 2005; 65: 11354-11360.
70. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999; 18: 4808-4818.
71. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas M, Gudkov A et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 2008; 27: 1905-1915.
72. Leontieva OV, Blagosklonny MV. Hypoxia and gerosuppression: the mTOR saga continues. Cell Cycle 2012; 11: 3926-3931.